Literature DB >> 6199050

Monoclonal antibodies against the complement control protein factor H (beta 1 H).

E Sim, M S Palmer, M Puklavec, R B Sim.   

Abstract

Two mouse monoclonal antibodies against the human complement control protein, Factor H (beta 1H), are described. The antibodies are both IgG - gamma 1 - subclass and are directed against different epitopes on the human Factor H molecule. One of the antibodies, MRC OX 24, increases the cofactor activity of Factor H in Factor I-mediated cleavage of soluble C3b. The second antibody, MRC OX 23, which has no effect alone, reduces the increase in cofactor activity observed in the presence of the first antibody. However, MRC OX 24 inhibits the binding of 125I-labelled Factor H to surface-bound C3b (EAC3b). Again MRC OX 23 alone does not have an effect but decreases the inhibition in 125I-labelled Factor H binding to EAC3b observed with MRC OX 24. These studies show clearly that the interaction of Factor H with soluble C3b is different to its interaction with surface-bound C3b. In an indirect immunoprecipitation system using these monoclonal antibodies, single-chain molecules of 150 000 mol.wt. are specifically precipitated from human serum and also from the sera of other primates - rhesus monkey, cynomolgus monkey, and African green monkey. There was no precipitation from sera of cow, pig, sheep, chick, or rabbit. Using a radioimmunoassay with radiolabelled monoclonal MRC OX 23, the concentration of Factor H in human plasma was determined.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6199050     DOI: 10.1007/BF01120205

Source DB:  PubMed          Journal:  Biosci Rep        ISSN: 0144-8463            Impact factor:   3.840


  27 in total

1.  Membrane-associated complement factor H on lymphoblastoid cell lines Raji expresses a co-factor activity for the factor I-mediated cleavage of C3b.

Authors:  M J Demares
Journal:  Immunology       Date:  1989-08       Impact factor: 7.397

2.  Factor H-IgG Chimeric Proteins as a Therapeutic Approach against the Gram-Positive Bacterial Pathogen Streptococcus pyogenes.

Authors:  Anna M Blom; Michal Magda; Lisa Kohl; Jutamas Shaughnessy; John D Lambris; Sanjay Ram; David Ermert
Journal:  J Immunol       Date:  2017-10-30       Impact factor: 5.422

3.  Human IgG Increases Virulence of Streptococcus pyogenes through Complement Evasion.

Authors:  David Ermert; Antonin Weckel; Michal Magda; Matthias Mörgelin; Jutamas Shaughnessy; Peter A Rice; Lars Björck; Sanjay Ram; Anna M Blom
Journal:  J Immunol       Date:  2018-04-06       Impact factor: 5.422

4.  The C-terminus of factor H: monoclonal antibodies inhibit heparin binding and identify epitopes common to factor H and factor H-related proteins.

Authors:  W M Prodinger; J Hellwage; M Spruth; M P Dierich; P F Zipfel
Journal:  Biochem J       Date:  1998-04-01       Impact factor: 3.857

5.  Interactions between human complement components factor H, factor I and C3b.

Authors:  C J Soames; R B Sim
Journal:  Biochem J       Date:  1997-09-01       Impact factor: 3.857

6.  The complete amino acid sequence of human complement factor H.

Authors:  J Ripoche; A J Day; T J Harris; R B Sim
Journal:  Biochem J       Date:  1988-01-15       Impact factor: 3.857

7.  Complement factor H-binding protein of Raji cells and tonsil B lymphocytes.

Authors:  A Erdei; R B Sim
Journal:  Biochem J       Date:  1987-08-15       Impact factor: 3.857

8.  Analysis of the interactions between properdin, the third component of complement (C3), and its physiological activation products.

Authors:  T C Farries; P J Lachmann; R A Harrison
Journal:  Biochem J       Date:  1988-05-15       Impact factor: 3.857

9.  Two populations of complement factor H differ in their ability to bind to cell surfaces.

Authors:  J Ripoche; A Erdei; D Gilbert; A Al Salihi; R B Sim; M Fontaine
Journal:  Biochem J       Date:  1988-07-15       Impact factor: 3.857

10.  Analysis of C3-receptor activity on human B-lymphocytes and isolation of the complement receptor type 2 (CR2).

Authors:  K J Micklem; R B Sim; E Sim
Journal:  Biochem J       Date:  1984-11-15       Impact factor: 3.857

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.